- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03923842
Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours (Dern)
Denosumab In Ebv Related Nasopharyngeal Carcinoma (Npc) As A Model For Rank-Mediated Immunologic Modulation Of Virus-Related Tumours - Dern Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately 15-20% of the cancers recognize infectious agents as causal factors. Epstein Barr Virus (EBV) is considered carcinogenic to humans for haematological and solid neoplasms such as nasopharyngeal carcinoma (NPC). Oncogenic mechanisms linking EBV with NPC need to be better delineated. However, the well-defined patterns of EBV cancer cells infection, together with its encoded regulated genes in tumours offers an option for immunological therapeutic strategies.
Distant metastases, especially of the bone, occurs in up to half of patients with NPC. This underlines the importance of improving systemic disease control.
Intravenous bisphosphonates (BP) are effective treatments for skeletal-related events (SRE) in patients with bone metastases. BPs also showed antitumor properties in solid malignancies by inhibiting cancer cell proliferation, inducing apoptosis and affecting bone microenvironment, increasing progression free survival (PFS) and overall survival (OS).
In head and neck squamous cell cancer, RANKL expression has been observed and correlated with tumour differentiation and progression. RANKL expression is also found in tumour-infiltrating Tregs. Once expressed, RANKL regulates epidermal dendritic cells and increases the number of Tregs, thereby suppressing excessive response to environmental stimuli. In NPC, the role of Tregs has been described and implicated in EBV-associated carcinogenesis.
Although no direct evidence of denosumab activity in NPC cells are available, its target's effect on Tregs is at the base of an indirect effect to tackle cancer immune evasion. In this scenario, treatment with RANK and RANKL inhibitors will supposedly act as positive immunoregulator reducing bone events but also improving treatment effects.
RANK expression was confirmed on 17 metastatic relapses of NPC treated at Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
The recent introduction of denosumab, a new drug active on bone metastases, with a different mechanism of action compared to BPs, changed the scenario. Denosumab is a fully human monoclonal antibody preventing the binding of RANKL to its receptor on osteoclasts' membrane. Denosumab is formulated for SC injection and for oncology indications is administered at a dose of 120 mg Q4W. Denosumab (120 mg SC) is approved worldwide for the prevention of SREs in patients with bone metastases from solid tumors and for the treatment of adults and skeletally mature adolescents with GCTB.
The above premises warrant the investigation of the activity of denosumab - an antibody competing with RANK, enhancing increasing tumour-specific immunity through the blockade of RANKL-regulated Tregs.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Lital Hollander, manager
- Phone Number: 003939014640
- Email: lital.hollander@gmail.com
Study Locations
-
-
-
Brescia, Italy
- Recruiting
- Asst Degli Spedali Civili Di Brescia
-
Contact:
- Paolo Bossi, MD
- Email: paolo.bossi@unibs.it
-
Milan, Italy, 20126
- Not yet recruiting
- Fondazione IRCCS Istituto Nazionale Tumori
-
Contact:
- Lisa Licitra, MD
- Phone Number: 2150 022390 2150
- Email: lisa.licitra@istitutotumori.mi.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- EBV related nasopharyngeal cancer
- Detectable and quantifiable plasmatic EBV DNA
- Recurrent and/or metastatic disease not suitable for curative treatment
- PS < 2
- Suitable for polychemotherapy
- Age ≥ 18 years
- Informed consent signed
Subject has adequate organ functions, evidenced by the following:
- AST (SGOT), ALT (SGPT) ≤ 2.5 x upper limit of normal range (ULN), or ≤ 5 x ULN range if liver metastasis present
- Total bilirubin ≤ 1.5 x ULN
- creatinine clearance 24/h > 50 mL/min
- Total serum calcium > 8.8 mg/dL
- Absolute neutrophil count ≥ 1.5 x 10*9 cells/L
- Platelets ≥ 100 x 10*9 cells/L
- Haemoglobin ≥ 9 g/dL
- If of childbearing potential, willingness to use effective contraceptive method (Pearl Index < 1; e.g. oral contraceptive (pill), hormone spiral, hormone implant, transdermal patch, a combination of two barrier methods (condom and diaphragm), sterilisation, sexual abstinence) for the study duration and 5 months post-dosing.
- Subject understands and voluntarily signs an ICF prior to any study-related assessments/procedures are conducted.
- Subject is able to adhere to the study visit schedule and other protocol requirements
Exclusion Criteria:
- Having received 1 or more chemotherapy line for recurrent/metastatic disease
- Any residual CTCAE grade ≥ 2 toxicity
- Subject has any other malignancy within 3 years prior to randomization, with the exception of adequately treated in situ carcinoma of the cervix, uteri, or non-melanoma skin cancer (all treatment of which should have been completed 6 months prior to enrolment), in situ squamous cell carcinoma of the breast, or incidental prostate cancer T1a, Gleason < 7, PSA <10 ng/ml.
- Subject has had radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting IP, and/or from whom ≥ 30% of the bone marrow was irradiated.
- Having participated in another clinical trial or having received any investigational agent in the preceding 30 days before study entry.
- Chronic systemic immunosuppressive therapy that cannot be interrupted during treatment study.
- Subject has significant active cardiac disease within the previous 6 months including unstable angina or angina requiring surgical or medical intervention, significant cardiac arrhythmia, or New York Heart Association (NYHA) class 3 or 4 congestive heart failure.
- Subject has a known or suspected hypersensitivity to study drugs.
- Subject is pregnant or breast feeding.
- Subject is receiving prohibited medication as per section 7.4.2 and suspension of such treatment is considered unsafe.
- Subject has history of prior or current osteonecrosis of the jaw (ONJ).
Subject has history of prior irradiation to the mandible, specified as:
Dose constraints to the mandible: Dmax = 70 Gy, V50 = 62 Gy and V60 = 20 Gy Mandible should be contoured as whole organ, with alveolar bone, excluding teeth
- Subject has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, contraindicate subject participation in the clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ARM A: Denosumab Treatment
Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles.
Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
|
Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles.
Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
Other Names:
|
ACTIVE_COMPARATOR: ARM B Control Arm
platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles.
At the end of the 6 cycles, if the patient is not progressing, can continue treatment with Gemcitabine alone.for
12 months
|
platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles.
Gemcitabine will continue for 12 months if the patient will not shown disease progression
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
plasmatic EBV DNA change
Time Frame: change in circulating EBV DNA levels from baseline (prior to the first denosumab administration on day -15 with respect to first chemotherapy administration
|
Meaningful plasmatic EBV DNA change in circulating EBV DNA levels from baseline (prior to the first denosumab administration on day -15 with respect to first chemotherapy administration) to the third denosumab dose (denosumab day 16, equivalent to chemotherapy treatment day 1).
|
change in circulating EBV DNA levels from baseline (prior to the first denosumab administration on day -15 with respect to first chemotherapy administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: PFS will be defined as the time from Chemotherapy treatment start (day1 for chemotherapy, day16 for denosumab) to disease progression or death from any cause.
|
PFS in patients treated or not with denosumab
|
PFS will be defined as the time from Chemotherapy treatment start (day1 for chemotherapy, day16 for denosumab) to disease progression or death from any cause.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute change in cellular immunity to EBV
Time Frame: prior to first denosumab administration, chemotherapy day -15 and denosumab day 1) and the subsequent planned time point (16 days, 2 and 6 months after denosumab treatment start
|
Cellular immunity will be defined blood lymphocytes activity against LMP and EBNA antigens.
Absolute change will be defined as the difference in such activity from baseline (i.e.
prior to first denosumab administration, chemotherapy day -15 and denosumab day 1) and the subsequent planned time point (16 days, 2 and 6 months after denosumab treatment start).
|
prior to first denosumab administration, chemotherapy day -15 and denosumab day 1) and the subsequent planned time point (16 days, 2 and 6 months after denosumab treatment start
|
Safety profile of denosumab plus chemotherapy: NCI CTCAE v 4.03
Time Frame: During study treatment anf follow up period
|
type and frequency of treatment-emergent adverse events, graded according to NCI CTCAE v 4.03
|
During study treatment anf follow up period
|
Absolute change in blood and salivary miRNA NPC profiles
Time Frame: at 16 days, 2 and 6 months after Denosumab treatment start
|
(chosen among selected miRNAs having previously shown correlation with immune activity and with NPC), measured at each planned time point (at 16 days, 2 and 6 months after Denosumab treatment start
|
at 16 days, 2 and 6 months after Denosumab treatment start
|
Absolute change of serum levels of RANKL and its inhibitor osteoprotegerin
Time Frame: at 16 days, 2 and 6 months after treatment start
|
Absolute change of serum levels of RANKL and its inhibitor osteoprotegerin (OPG), measured at each planned time point
|
at 16 days, 2 and 6 months after treatment start
|
Absolute change in EBV DNA levels at each other planned time point
Time Frame: at 2 months after denosumab treatment start, prior to administration of 3rd denosumab treatment, and at 6 months, prior to administration of 7th denosumab treatment
|
change in EBV DNA levels
|
at 2 months after denosumab treatment start, prior to administration of 3rd denosumab treatment, and at 6 months, prior to administration of 7th denosumab treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Paolo Bossi, Dr., Università degli Studi di Brescia ASST degli Spedali Civili di Brescia
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Nasopharyngeal Neoplasms
- Carcinoma
- Nasopharyngeal Carcinoma
- Physiological Effects of Drugs
- Bone Density Conservation Agents
- Denosumab
Other Study ID Numbers
- 2017-005017-31
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasopharyngeal Carcinoma
-
National Cancer Institute (NCI)NRG OncologyTerminatedRecurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Metastatic Nasopharyngeal Nonkeratinizing Carcinoma | Metastatic Nasopharyngeal Undifferentiated Carcinoma | Nasopharyngeal... and other conditionsUnited States, Canada, China, Singapore
-
National Cancer Institute (NCI)CompletedRecurrent Nasopharynx Carcinoma | Stage III Nasopharyngeal Carcinoma AJCC v7 | Stage IV Nasopharyngeal Carcinoma AJCC v7 | Stage IVA Nasopharyngeal Carcinoma AJCC v7 | Stage IVB Nasopharyngeal Carcinoma AJCC v7 | Stage IVC Nasopharyngeal Carcinoma AJCC v7 | Nasopharyngeal Nonkeratinizing CarcinomaUnited States, Singapore, China
-
National Cancer Institute (NCI)Radiation Therapy Oncology GroupCompletedStage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7 | Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage III Nasopharyngeal...United States, Canada
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedStage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7 | Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7 | Stage II Nasopharyngeal Keratinizing... and other conditionsUnited States, Canada, Australia
-
Alliance for Clinical Trials in OncologyNot yet recruitingRecurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma
-
Alain AlgaziAstraZeneca; Incyte CorporationWithdrawnRecurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma | Epstein-Barr Virus Positive | Stage III Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Carcinoma
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownLOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNTFrance
-
Stanford UniversityTerminatedStage IV Nasopharyngeal Carcinoma | Stage III Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Carcinoma | Stage II Nasopharyngeal Carcinoma | Stage 0 Nasopharyngeal Carcinoma | Stage 0 Paranasal Sinus Cancer | Stage I Nasopharyngeal Carcinoma | Stage I Paranasal... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IV Nasopharyngeal Carcinoma AJCC v8 | Stage II Nasopharyngeal Carcinoma AJCC v8 | Stage III Nasopharyngeal Carcinoma AJCC v8
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRecurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal CarcinomaChina
Clinical Trials on Denosumab Inj 120 MG/1.7ML
-
Natasha Appelman-DijkstraRecruitingFibrous Dysplasia | McCune Albright SyndromeNetherlands
-
Borstkanker Onderzoek GroepAmgenWithdrawn
-
Thomas Nickolas, MD MSTerminatedOsteoporosis | Kidney Transplant; Complications | Renal OsteodystrophyUnited States
-
Institut Català d'OncologiaAmgenActive, not recruitingStage I Breast Cancer | Breast Neoplasm Female | Stage II Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative NeoplasmSpain
-
Luye Pharma Group Ltd.Shang Dong Boan Biotechnology Co., Ltd (Co-sponsor)UnknownHealthy Adults
-
European Organisation for Research and Treatment...AmgenTerminatedBone Giant Cell TumorSpain, United Kingdom, Italy, Netherlands
-
Hamad Medical CorporationTerminatedOsteoporosis | Thalassemia Majors (Beta-Thalassemia Major)Qatar
-
Arbeitsgemeinschaft medikamentoese TumortherapieAmgen; Assign Data Management and Biostatistics GmbHActive, not recruitingMultiple MyelomaAustria, Germany, Israel
-
Hoffmann-La RocheChugai Pharmaceutical Co.TerminatedNeuromyelitis Optica Spectrum Disorder | NMOSDUnited States, Korea, Republic of, Italy, Canada, Japan, Turkey